Glucagon-like peptide-1 (GLP-1) analogues have been widely used in the treatment of diabetes and obesity, and multi-receptor agonists that combine GLP-1 analogues with other intestinal hormones such as glucose-dependent insulin-stimulating peptide (GIP) and glucagon (GCG) are in clinical development. Compared with GLP-1 analogues, multi-receptor agonists can exert multiple physiological effects and have better effects in controlling blood glucose and reducing body weight with fewer side effects, which are expected to be a new therapy for diabetes and obesity. In this paper, we reviewed the development of intestinal hormone multi-receptor agonists, summarized their design ideas and clinical manifestations, and provided reference for the development of multi-receptor agonists.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |